Peripheral Vascular Disease
100,000 Patient Meta-Analysis Shows Carotid Intima-Media Thickness Progression Can Be Used as a Surrogate Marker for Cardiovascular Risk
A recent meta-analysis of clinical trials with more than 100,000 patients has shown that the carotid intima-media thickness (cIMT) progression can be used as a surrogate marker for cardiovascular risk in the clinical trials. The results of this study published in Circulation. According to Dr. Willeit, the assessment of cIMT progression can provide a link for the development and license of new therapies for cardiovascular disease. Continue reading
Long-Term Follow-Up of the REDUCE-MVI Trial Showed the Superiority of Ticagrelor Over Prasugrel in Maintenance Therapy of Patients With ST-Segment-Elevation Myocardial Infarction
A recent study by Dr. van der Hoeven, published in the Journal of American Heart Association, has shown the superiority of ticagrelor over prasugrel in patients presenting with ST-segment-elevation myocardial infarction (STEMI). According to the author, ticagrelor has a higher efficacy in platelet inhibition as well as in improving endothelial function when compared with prasugrel. Continue reading
11-Year Follow-Up Study Shows Drug Eluting Devices Safe in Patients with Peripheral Vascular Disease
The results of a real-world safety analysis showed that over a follow-up period of up to 11 years, there was no evidence of increased mortality in patients who underwent endovascular revascularization of peripheral vessels with paclitaxel-based drug-eluting devices (DED). In this analysis, led by Dr. Eva Freisinger published in the European Heart Journal, the investigators offer evidence that conflicts with the data that suggests paclitaxel-based DED is associated with increased mortality risk.
Long-Term Risk of Death Shows Dramatic Increase Following Femoropopliteal Application of Paclitaxel-Coated Balloons and Stents A Systematic Review and Meta-Analysis of Randomized Controlled Trials
The results of a systematic review and meta-analysis of randomized controlled trials conducted by Konstantinos Katsanos and his colleagues have showcased an increased risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the lower limbs. Further investigations are urgently warranted, the authors state in their publication in Circulation. Continue reading
Drug-Coated Balloon Outperforms Percutaneous Transluminal Angioplasty in Femoropopliteal Disease 24-Month Results of AcoArt I
A study conducted by Yongle Xu et al. demonstrated that the superiority of Drug-Coated Balloon (DCB) versus percutaneous transluminal angioplasty (PTA) in the efficacy of femoropopliteal artery disease (FPAD) treatment persists at 24-month follow-up. The findings, which were published online in JACC: Cardiovascular Interventions, also showed that the safety of DCB was equivalent to that of PTA. Continue reading
Vascular Video Series Part 9: AHA’s Goal for Reducing Cardiovascular Death by 20% in 2020 Dr. Libby, Dr. Bonaca, and Dr. Gibson Discuss
This video is supported by an unrestricted educational grant.
Vascular Video Series Part 8: What the Future Holds for Antithrombotic Therapies Dr. Libby, Dr. Bonaca, and Dr. Gibson Discuss
This video is supported by an unrestricted educational grant.
Vascular Video Series Part 7: Biology and Pathways of Treatment in Atherosclerotic Patients Dr. Libby, Dr. Bonaca and Dr. Gibson Discuss
This video is supported by an unrestricted educational grant.
Polymer coated sustained-release Eluvia DES outshines non-polymer coated Zilver DES for femoropopliteal artery stenosis Clinical outcomes at 1 year presented at TCTMD 2018
A randomized global, prospective, multi-center, single-blind trial comparing the Eluvia paclitaxel-eluting stent (Boston Scientific) to Zilver PTX paclitaxel-eluting stent (Cook Medical) has shown that the Eluvia stent outperformed Zilver in terms of efficacy, which was defined as primary patency at 12 months. These findings, published in The Lancet, were presented by Dr. William Gray at the annual TCT 2018 conference held in San Diego today. Continue reading
Vascular Video Series Part 6: Gaps in Vascular Care Dr. Libby, Dr. Bonaca, and Dr. Gibson Discuss
This video is supported by an unrestricted educational grant.
Vascular Video Series Part 5: Gaps in Vascular Care Dr. Libby, Dr. Bonaca, and Dr. Gibson Discuss
This video is supported by an unrestricted educational grant.
Vascular Video Series Part 4: Vascular Risk Dr. Libby, Dr. Bonaca, and Dr. Gibson Discuss
This video is supported by an unrestricted educational grant.
Vascular Video Series Part 3: The Polyvascular Disease Patient Dr. Libby, Dr. Bonaca, and Dr. Gibson Discuss
This video is supported by an unrestricted educational grant.
Vascular Video Series Part 2: Underlying Risks of Vascular Disease Dr. Libby, Dr. Bonaca, and Dr. Gibson Discuss
This video is supported by an unrestricted educational grant.
Vascular Video Series Part 1: Clinical Manifestations of Atherosclerosis Dr. Libby, Dr. Bonaca, and Dr. Gibson Discuss
This video is supported by an unrestricted educational grant.
Benefit of Abdominal Aortic Aneurysm Screening In Question Swedish Registry Based Cohort Study
Screening for abdominal aortic aneurysm (AAA) does not contribute to a significant reduction in mortality, according to a registry study that has been recently published in The Lancet.
Low Dose Rivaroxaban Plus Aspirin Reduces Major Adverse Limb Events in COMPASS A COMPASS subgroup analysis
According to a new subgroup analysis of the COMPASS trial published in the Journal of the American College of Cardiology, the prevention of Major Adverse Limb Events (MALE) is of utmost importance in patients with lower extremity Peripheral Arterial Disease (PAD) due to its poor prognosis. Additionally, it has been found that the aspirin and rivaroxaban 2.5mg twice daily combination leads to a significant reduction of Major Adverse Limb Events (MALE) in these patients.
